Market Place
Sourcing Support
Aptar takes up option on Orbital high dose dry powder inhaler
09 Aug 2022 //
FIERCEPHARMA
Aptar Pharma Acquires Worldwide Rights to Pharmaxis’ Orbital Inhaler
05 Aug 2022 //
CONTRACTPHARMA
FDA Clears Pharmaxis Cancer Drug to Progress to Phase 2 Study in Liver Cancer
09 Nov 2021 //
PRNEWSWIRE
Pharmaxis Cleared To Progress To Phase 2 Bone Marrow Cancer Trial
05 Oct 2021 //
PRNEWSWIRE
Pharmaxis Treatment to Prevent Wound and Burns Scars Clears Phase 1 Trial
31 Aug 2021 //
PRNEWSWIRE
Aptar Pharma, Pharmaxis Enter Orbital DPI Agreement
17 Aug 2021 //
CONTRACT PHARMA
Pharmaxis Cancer Drug Decreases Tumour Burden in Pre Clinical Liver Cancer Model
05 Aug 2021 //
PRNEWSWIRE
Pharmaxis Sells Bronchitol and Aridol Australian Distribution Rights for A$2m
01 Jul 2021 //
PRESS RELEASE
Pharmaxis Announces First Results in Bone Marrow Cancer Trial
29 Jun 2021 //
PROACTIVEINVESTORS
Pharmaxis Announces Progression of Clinical Trial in Bone Marrow Cancer
10 Jun 2021 //
PHARMIWEB
Pharmaxis begins exporting its cystic fibrosis drug Bronchitol® to the USA
09 Feb 2021 //
PROACTIVEINVESTORS
Boehringer Discontinues Development of BI 1467335 for Diabetic Retinopathy
07 Sep 2020 //
PIPELINE REVIEW
Boehringer`s $250M NASH drug hits the skids as development path gets rockier
19 Dec 2019 //
FIERCE BIOTECH
Pharmaxis announces +ve results from phase 1 trial for second LOXL2 inhibitor
20 Nov 2018 //
PHARMABIZ
Boehringer initiates Phase IIa study of compound acquired from Pharmaxis
24 Aug 2017 //
PR NEWSWIRE
Synairgen eyes lung fibrosis trial after positive data from LOXL2 inhibitor
13 Mar 2017 //
PBR
Pharmaxis completes treatment phase in clinical trial for U.S. market
22 Feb 2017 //
PROACTIVE INVESTOR
Pharmaxis Releases Results of Phase 1 Clinical Trial for PXS-4728A
21 Sep 2015 //
PR NEWS WIRE
Pharmaxis, Synairgen to develop LOXL2 inhibitor for pulmonary fibrosis
06 Aug 2015 //
PBR
Pharmaxis and Synairgen Announce Research Collaboration to Develop LOXL2 Inhibitor For Pulmonary Fibrosis
05 Aug 2015 //
PR NEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.